> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Protara Loses $21.7 Million As Trial Costs Rise — Cash Expected To Last Into 2028
- URL: https://www.bullished.co/protara-loses-21-7-million-as-trial-costs-rise-cash-expected-to-last-into-2028-c304906d/
- Published: 2026-11-06T13:20:57.000Z
- Updated: 2026-11-06T13:20:57.000Z
- Description: The drug developer bought manufacturing assets for $8.75 million and expects bladder-cancer trial enrollment to finish by year-end.
- Author: Matteo Parrino
- Tags: SEC Filings, TARA, Industry: Healthcare

Protara Therapeutics, which develops experimental cancer and rare-disease treatments, reported a third-quarter loss of [$21.7 million](https://www.sec.gov/Archives/edgar/data/0001359931/000121390026116607/ea0309567-8k%5Fprotara.htm?ref=bullished.co) Friday, compared with $13.3 million a year earlier, as clinical-trial and development spending increased. In results accompanying its SEC filing, the company said its $143.1 million of unrestricted cash, cash equivalents and debt investments at September 30 should fund planned operations and milestones into 2028.

## Clinical Trials Drive Higher Spending

Research and development spending reached $16.8 million for the third quarter, versus $9.6 million a year earlier. Protara attributed the increase chiefly to $4.4 million more in direct clinical-trial costs, $2.0 million more in personnel costs and $0.8 million more in research expenses largely tied to manufacturing development for TARA-002.

Administrative expenses reached $6.3 million, compared with $5.2 million. Personnel and other administrative costs each contributed $0.6 million to the increase, according to the company.

The quarterly loss amounted to $0.35 per share, versus $0.31 a year earlier. For the first nine months, the company’s net loss was $61.138 million against $40.132 million; operating expenses totaled $66.107 million against $45.470 million.

## An $8.75 Million Manufacturing Purchase

Protara completed an [$8.75 million purchase](https://www.sec.gov/Archives/edgar/data/0001359931/000121390026116607/ea030956701ex99-1.htm?ref=bullished.co) of TARA-002 manufacturing assets from Novex Innovations. The purchase agreement was signed Wednesday, and Novex has made the therapy for Protara since 2019.

The acquisition gives Protara dedicated manufacturing capacity ahead of a potential commercial launch. Along with equipment, inventory and intellectual property, the purchase included a workforce; Protara also leased a research and manufacturing facility.

Jesse Shefferman, chief executive officer of Protara Therapeutics, said, “We are excited to bring this [manufacturing capability in-house](https://www.sec.gov/Archives/edgar/data/0001359931/000121390026116607/ea030956701ex99-1.htm?ref=bullished.co) as we advance our late-stage clinical trials and prepare to launch TARA-002 in lymphatic malformations (LMs) and NMIBC.”

TARA-002 is a cell therapy being tested for bladder cancer that has not reached the bladder muscle and for lymphatic malformations—rare, noncancerous cysts that primarily affect children. Neither TARA-002 nor Protara’s other candidate, intravenous choline chloride, is approved for sale, and the New York City-based company has generated no product-sales revenue.

## Enrollment Targets Span 2026 And 2027

Protara expects to finish enrollment by year-end 2026 in the bladder-cancer trial cohort for patients whose disease did not respond to BCG treatment. During the third quarter, the company also announced plans to redesign another bladder-cancer trial to study TARA-002 across a wider range of high-risk disease and prior BCG exposure.

For lymphatic malformations, enrollment is now expected to finish early in the first quarter of 2027\. Protara expects to begin submitting its FDA approval application in stages in the second half of 2027, following discussions with the agency under the program’s Breakthrough Therapy designation.

The intravenous choline chloride program has completed enrollment of 24 patients in its mid-stage dose-confirmation study. The trial evaluates adolescents and adults with intestinal failure and choline deficiency who depend on nutrition and fluids delivered intravenously.

Protara expects interim results from the choline chloride dosing study by year-end 2026—the same deadline it has set for completing enrollment in its BCG-unresponsive bladder-cancer cohort.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Protara Therapeutics, Inc. (TARA)](https://www.sec.gov/Archives/edgar/data/0001359931/000121390026116607/ea0309567-8k%5Fprotara.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit ea030956701ex99-1.htm — Protara Therapeutics, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001359931/000121390026116607/ea030956701ex99-1.htm?ref=bullished.co) — SEC EDGAR
- [Protara Therapeutics Announces Third Quarter 2026 Financial](https://www.globenewswire.com/news-release/2026/11/06/3397475/0/en/protara-therapeutics-announces-third-quarter-2026-financial-results-and-provides-a-business-update.html?ref=bullished.co) — globenewswire.com